Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

mRNA-3705

Generic Name: mRNA-3705

Drug Type: Biotech

Overview

mRNA-3705 is an investigational mRNA encoding methylmalonic CoA mutase (MUT) enzyme. Developed by Moderna TX Inc., it is being investigated for the treatment of methylmalonic academia.

Background

mRNA-3705 is an investigational mRNA encoding methylmalonic CoA mutase (MUT) enzyme. Developed by Moderna TX Inc., it is being investigated for the treatment of methylmalonic academia.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705

Phase 1

Recruiting

Posted: 2022/03/25

Sponsor:ModernaTX, Inc.

ID:NCT05295433

A Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants With Isolated Methylmalonic Acidemia

Phase 1

Recruiting

Posted: 2021/05/24

Sponsor:ModernaTX, Inc.

ID:NCT04899310

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

FDA's START Program Selects First Rare Disease Therapies for Accelerated Development

4 months ago

The FDA's START program, designed to expedite rare disease therapy development, has chosen its first candidates for enhanced guidance and support.

Moderna Reports $3.2 Billion in 2024 Revenue, Submits Three mRNA Products for Regulatory Approval

4 months ago

Moderna reported $3.2 billion in total revenue for fiscal year 2024, with a net loss of $3.6 billion as the company transitions from pandemic to seasonal COVID-19 vaccine market.

Moderna Faces Investor Concerns Despite Pipeline Progress and Cost-Cutting Efforts

5 months ago

Moderna's stock has significantly dropped in 2024 due to waning COVID-19 vaccine demand, despite positive data and new approvals.

Moderna Restructures Pipeline, Prioritizes Key Approvals, and Cuts R&D Spending

8 months ago

Moderna is reducing its research and development expenses by 20%, aiming for $16 billion between 2025 and 2028, to focus on profitability.

Moderna's Combo COVID-19 and Flu Vaccine Shows Promising Results in Early Trial

2 years ago

Moderna announced positive data from an early-stage study of its mRNA-based combination vaccine for COVID-19 and influenza, showing similar or stronger immune responses compared to standalone vaccines in older adults.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy